SPP1 / OPN Alleviates Post‐Intracerebral Hemorrhage Depression and Cognitive Impairment via Nrf2 / BDNF Signaling Activation in Mice
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1002/cns.70680 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Pengpeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China. Hauptthemen laut MEDLINE: Osteopontin, NF-E2-Related Factor 2, Brain-Derived Neurotrophic Factor, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China-Henan Joint Fund.
Themen: Depression
Abstract (Originalsprache)
Background
Post‐stroke depression represents a prevalent neuropsychiatric complication following intracerebral hemorrhage (ICH), yet its underlying mechanisms remain less understood compared to ischemic stroke.
Methods
This translational investigation employed a multi‐omics approach, combining bioinformatics analysis of depression‐related (GSE214921) and ICH‐related (GSE18193) datasets from the GEO database with experimental validation. Using a collagenase‐induced striatal ICH murine model, we evaluated the effects of intranasal administration of osteopontin (OPN, encoded by SPP1) through neurobehavioral tests, histopathological evaluation, and molecular biology techniques.
Results
Integrated bioinformatics analysis identified the SPP1 signaling pathway as a potential key regulator in post‐ICH depression pathogenesis. In vivo, OPN treatment produced sustained neurobehavioral improvements at 28 days post‐ICH, significantly ameliorating neurological deficits, mitigating anxiety‐depressive behaviors, and enhancing spatial learning‐memory performance. Histopathological evaluation revealed OPN's multifaceted neuroprotective effects, including attenuated hippocampal neuroinflammation, preserved Nissl body integrity, and restored dendritic arborization complexity. Mechanistically, OPN exerted its therapeutic effects through activation of the Nrf2/BDNF signaling axis, as pharmacological inhibition of Nrf2 with ML385 completely abrogated both neuroprotection and BDNF upregulation.
Conclusion
Our study is the first to demonstrate the critical role of SPP1 signaling in post‐ICH depression through modulation of the Nrf2/BDNF pathway, providing novel therapeutic targets for clinical management of this debilitating neuropsychiatric sequela.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
- Department of Neurosurgery, Jiangnan University Medical Center, Wuxi, Jiangsu, China.
- Wuxi No. 2 People's Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, China.
- Ningxia Medical University, Yinchuan, China.
- Department of Neurosurgery, Medical School of Nantong University, Nantong University, Nantong, China.
- Wuxi Neurosurgical Institute, Wuxi, Jiangsu, People's Republic of China.
Förderung
- National Natural Science Foundation of China-Henan Joint Fund
Zitieren
APA
Li, P., Gao, Y., Du, S., Mu, Z., Tao, Z., Zhang, X., & Zhao, X. (2025). SPP1 / OPN Alleviates Post‐Intracerebral Hemorrhage Depression and Cognitive Impairment via Nrf2 / BDNF Signaling Activation in Mice. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70680
Vancouver
Li P, Gao Y, Du S, Mu Z, Tao Z, Zhang X, et al. SPP1 / OPN Alleviates Post‐Intracerebral Hemorrhage Depression and Cognitive Impairment via Nrf2 / BDNF Signaling Activation in Mice. CNS Neuroscience & Therapeutics. 2025. doi:10.1002/cns.70680
BibTeX
@article{Li2025,
author = {Li, Pengpeng and Gao, Yangyang and Du, Shiqing and Mu, Zhengqian and Tao, Zhenxing and Zhang, Xuqi and Zhao, Xudong},
title = {SPP1 / OPN Alleviates Post‐Intracerebral Hemorrhage Depression and Cognitive Impairment via Nrf2 / BDNF Signaling Activation in Mice},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1002/cns.70680}
}
EUVIMED